We performed a spine focused, stepwise escalating imaging set.
In children with persistent disease activity the Anakinra dose was stepwise escalated to a maximum of 8 mg/kg.
Ten pigs, 40 to 90 kg, anaesthetized, fully mechanically ventilated at 6 to 8 mg/kg were subject to stepwise escalating levels of PEEP at 2-minute intervals (0, 5, 10, 15, 20, 25 and 30 cmH2O).
PTX-resistant sublines (SKpac and A2780pac) were produced from parent cell line, SKOV3 and A2780, respectively, by continuous exposure of cells to a stepwise escalating concentration of PTX over 8 months.
Six different PTX-resistant sublines (SKpac-8, -10, -11, -12, -16, and -17) were generated from the parent cell line (SKOV3) by continuous exposure of a stepwise, escalating concentration of PTX over a period of 12 months.
The present study differs from those studies in that the dose was only escalated in stepwise manner for patients who did not experience neutropenia.
The decision to escalate in the stepwise approach from one pre-meal bolus dose to two and then possibly three doses should be made on the basis of HbA1C levels.
The dose was escalated in a stepwise manner with a total of six patients at the putative MTD.
Doses were escalated in a stepwise fashion if fewer two out of three patients in a dose cohort experienced a DLT.
Subsequently, whenever synovitis was present MTX dose was escalated by 2.5 mg from 7.5 mg/week to maximum 20 mg/week followed by a stepwise cyclosporine/placebo-cyclosporine increment (0.5 mg/kg) every four weeks from 2.5 mg/kg to maximum 4.0 mg/kg.
Stepwise subsampling was performed.
